News: Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

95.41EUR
15 Aug 2014
Price Change (% chg)

€-2.28 (-2.33%)
Prev Close
€97.69
Open
€97.78
Day's High
€98.45
Day's Low
€95.03
Volume
2,510,992
Avg. Vol
1,677,797
52-wk High
€106.80
52-wk Low
€81.82

Search Stocks
Select another date:

Fri, Aug 29 2014

Germany's Bayer to launch three new Xarelto trials

FRANKFURT - Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines.

UPDATE 1-Germany's Bayer to launch three new Xarelto trials

* Bayer won't say whether it may raise peak sales estimate (Adds senior manager quotes, further details of trials)

Germany's Bayer to launch three new Xarelto trials

FRANKFURT, Aug 29 - Germany's Bayer said it plans to launch three new studies to add more uses for its anti-clotting drug Xarelto, one of its top five new medicines.

Fitch Assigns Bayer AG's Hybrid Notes 'BBB+', 50% Equity Credit; Affirms IDR at 'A'

(The following statement was released by the rating agency) LONDON, August 13 (Fitch) Fitch Ratings has assigned Bayer AG's EUR1.75bn and EUR1.5bn subordinated resettable floating-rate notes a rating of 'BBB+', two notches below Bayer's Issuer Default Rating (IDR) of 'A' in line with the existing hybrid notes. Fitch has applied a 50% equity credit to the two bonds, which are identical in ranking and terms with exception of maturity and pricing. Fitch has also affirmed Bayer's IDR at 'A' wit

BRIEF-Bayer receives EU approval for Eylea in diabetic macular edema

Aug 11 - Bayer AG : * Says receives EU approval for Eylea in diabetic macular edema * Says plans for an immediate roll-out with Germany being one of the first

Bayer says discussing size of animal health unit

FRANKFURT, July 30 - German healthcare group Bayer is discussing internally whether its animal health unit needs to be bulked up to better compete with rivals, its chief executive said.

UPDATE 2-Bayer's new drug boost dampened by strong euro

* Sees 41 bln euros in 2014 sales vs 41-42 bln previously

BRIEF-Bayer's Regorafenib wins EU approval for treatment of gastrointestinal tumors

July 30 - Bayer AG : * Says regorafenib (Stivarga) approved in the European union for the treatment of gastrointestinal stromal tumors Source text: http://bit.ly/1oJQTkj

BRIEF-Bayer's Eylea receives FDA approval for the treatment of diabetic macular edema

July 30 - Bayer AG : * Says Eylea receives FDA approval for the treatment of diabetic macular edema

German stocks - Factors to watch on July 30

FRANKFURT, July 30 - The DAX top-30 index looked set to open 0.1 percent lower on Wednesday, according to premarket data from brokerage Lang & Schwarz at 0603 GMT.

Select another date:

Press Releases

Search Stocks